The X-Rad SmART+ Biological Irradiator for Pre-Clinical Oncology Research

7.项目概要/摘要。 该申请要求为最先进的共享资源提供资金，即X-Rad小动物辐射 治疗（SmART）+生物辐照器（Precision X-Ray，North Branford，CT），以取代我们现有的X- Rad 225Cx生物辐照器（也由Precision X-Ray制造）。根据精密X射线的"结束- EOL（生命周期结束）是2020年12月31日的日期，在此之后，我们将不再能够 根据新的支助协定为该股提供服务和/或提供支助"。（精密X射线随后同意， 为我们的X-Rad 225Cx生物辐照器（不包括X射线管和发生器）提供服务支持 至2021年12月31日）。当然，放射治疗（RT）仍然是最广泛使用的， 有效的癌症治疗方式，和纪念斯隆凯特琳癌症中心（MSK）长期以来一直是 被公认为RT研究、开发和患者护理领域的全球领导者。 2014年，我们大量使用的X-Rad 225Cx生物辐照器为这一传统做出了巨大贡献， 宝贵的技术能力，为NIH资助的基础和翻译研究的反应， 正常组织和肿瘤在实验啮齿动物模型治疗外束照射。临床- 分级外射束放射治疗现在是临床前肿瘤学研究的重要组成部分 在MSK的节目。所要求的仪器，最先进的X-Rad SmART+，是一种图像引导， 等中心（360度旋转，具有电弧治疗能力），自屏蔽研究辐照器结合高 分辨率（100 μ m）锥形束CT成像系统和高剂量率（高达约5戈伊/min） 将治疗X射线源整合到一个单一的集成计算机控制平台中。它包括各种各样的 固定场准直器-圆形（直径0.5至25 mm）、方形（3 x 3至40 x 40 mm）和矩形（8 x 10 mm） 12至30 x 40 mm）-加上一个可适应的场成形准直器。X-Rad SmART+还包括SmART- ATP（高级治疗计划），一种临床级基于蒙特卡罗建模的治疗计划系统。 与其前身X-Rad 225Cx相似，X-Rad SmART+生物辐照器是一种复杂的仪器 需要由供应商及时提供服务和应用程序支持以及定期软件更新， 确保尖端且通常对时间敏感的实验工作所需的可靠性能。没有 这样的支持，重要的资助实验将受到非常严重的损害或完全放弃。 因此，X-Rad SmART+生物辐照器对于许多高生产率， MSK临床前肿瘤学研究计划中的NIH资助项目。

7. Project Summary/Abstract. This application requests funds for a state-of-the-art shared resource, the X-Rad Small-Animal Radiation Therapy (SmART)+ Biological Irradiator (Precision X-Ray, North Branford, CT), to replace our existing X- Rad 225Cx Biological Irradiator (also manufactured by Precision X-Ray). Pursuant to Precision X-Ray’s “end- of-life” letter, “…the EOL (End Of Life) is the date - December 31st, 2020 - after which we will no longer be able to service and/or cover the unit under a new support agreement.” (Precision X-Ray subsequently agreed to provide service support for our X-Rad 225Cx Biological Irradiator exclusive of the X-ray tube and generator through December 31st, 2021.) Radiation therapy (RT) remains, of course, one of the most widely used and effective cancer treatment modalities, and Memorial Sloan Kettering Cancer Center (MSK) has long been recognized as a worldwide leader in research, development, and patient care in RT. Since its installation in 2014, our heavily used X-Rad 225Cx Biological Irradiator has contributed enormously to this legacy, providing invaluable technical capabilities for NIH-funded basic and translational investigations on the response of normal tissues and tumors in experimental rodent models to therapeutic external-beam irradiation. Clinical- grade external-beam radiation therapy is now an essential component of the pre-clinical oncology research program at MSK. The instrument requested, the state-of-the-art X-Rad SmART+, is an image-guided, isocentric (360 rotation, with arc therapy capability), self-shielded research irradiator combining a high- resolution (100 m) cone-beam CT imaging system and a high-dose rate (up to approximately 5 Gy/min) therapeutic X-ray source into a single integrated, computer-controlled platform. It includes a wide variety of fixed-field collimators – circular (0.5 to 25 mm in diameter), square (3 x 3 to 40 x 40 mm), and rectangular (8 x 12 to 30 x 40 mm) – plus an adaptable field-shaping collimator. The X-Rad SmART+ also includes SmART - ATP (Advanced Treatment Planning), a clinical-grade Monte Carlo modeling-based treatment planning system. Similar to its predecessor, the X-Rad 225Cx, the X-Rad SmART+ Biological Irradiator is a complex instrument requiring timely manufacturer-provided service and applications support and periodic software updates to ensure the reliable performance which cutting-edge, often time-sensitive experimental work demands. Without such support, important funded experiments would be very seriously compromised or abandoned altogether. The X-Rad SmART+ Biological Irradiator is thus essential for the ongoing work of numerous highly productive, NIH-funded projects in MSK’s pre-clinical oncology research program.